viale-c
由 B Tbakhi 著作 · 2020 — The FDA's continued approval, however, was to be dependent on two randomized phase III trials, VIALE-A and VIALE-C, that combined venetoclax ...,ABT-199; Venclexta. Drug: Cytarabine. Subcutaneous injection. Other Names: Cytosar-U; Ara-C; Arabinosylcytosine.,由 AH Wei 著作 · 2020 · 被引用 164 次 — Effective treatment options are limited for patients with acute myeloid leukemia (AML) who cannot tolerate intensive chemotherapy.,由 AH Wei 著作 · 2020 · 被引用 164 次 — Kumar S, Kaufman JL, Gasparetto C, et al. . Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma.,On February 28, 2020, it was announced that the VIALE-C trial, comparing venetoclax plus low dose cytarabine (LDAC) to placebo plus LDAC, failed to meet the ...,2020年9月9日 — The extended findings from the phase 3 VIALE-C trial position low-dose cytarabine (LDAC) plus the BCL-2 inhibitor venetoclax as a potential ...,由 CD DiNardo 著作 · 2020 · 被引用 358 次 — (Funded by AbbVie and Genentech; VIALE-A ClinicalTrials.gov number, NCT02993523. opens in new tab.) Introduction.,2020年2月28日 — The VIALE-C study evaluated venetoclax in combination with LDAC compared with LDAC alone in newly-diagnosed patients with AML who are ...,2020年6月12日 — VIALE-C was designed to compare the safety and efficacy of the BCL-2 inhibitor venetoclax (VEN) or placebo (PBO) plus low-dose cytarabine (LDAC) ...,EHA25 Virtual: 6-Month VIALE-C Update on Venetoclax With Low-Dose Cytarabine in AML. By: Joseph Fanelli Posted: Wednesday, July 8, 2020.
| 相關軟體 HMA! Pro VPN 資訊 | |
|---|---|
 viale-c 相關參考資料
The VIALE-C Trial: Venetoclax and Low-dose Cytarabine in ...
由 B Tbakhi 著作 · 2020 — The FDA's continued approval, however, was to be dependent on two randomized phase III trials, VIALE-A and VIALE-C, that combined venetoclax ... https://ashpublications.org NCT03069352 - ClinicalTrials.gov
ABT-199; Venclexta. Drug: Cytarabine. Subcutaneous injection. Other Names: Cytosar-U; Ara-C; Arabinosylcytosine. https://clinicaltrials.gov Venetoclax plus LDAC for newly diagnosed AML ... - PubMed
由 AH Wei 著作 · 2020 · 被引用 164 次 — Effective treatment options are limited for patients with acute myeloid leukemia (AML) who cannot tolerate intensive chemotherapy. https://pubmed.ncbi.nlm.nih.go Venetoclax plus LDAC for newly diagnosed AML ... - NCBI
由 AH Wei 著作 · 2020 · 被引用 164 次 — Kumar S, Kaufman JL, Gasparetto C, et al. . Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma. https://www.ncbi.nlm.nih.gov Phase III VIALE-C trial - AML Hub
On February 28, 2020, it was announced that the VIALE-C trial, comparing venetoclax plus low dose cytarabine (LDAC) to placebo plus LDAC, failed to meet the ... https://aml-hub.com OS benefit in VIALE-C trial - Medical Conferences
2020年9月9日 — The extended findings from the phase 3 VIALE-C trial position low-dose cytarabine (LDAC) plus the BCL-2 inhibitor venetoclax as a potential ... https://conferences.medicom-pu Azacitidine and Venetoclax in Previously Untreated Acute ...
由 CD DiNardo 著作 · 2020 · 被引用 358 次 — (Funded by AbbVie and Genentech; VIALE-A ClinicalTrials.gov number, NCT02993523. opens in new tab.) Introduction. https://www.nejm.org AbbVie Provides Update from Phase 3 Study Evaluating ...
2020年2月28日 — The VIALE-C study evaluated venetoclax in combination with LDAC compared with LDAC alone in newly-diagnosed patients with AML who are ... https://news.abbvie.com a phase 3 study of venetoclax plus low-dose cytarabine in ...
2020年6月12日 — VIALE-C was designed to compare the safety and efficacy of the BCL-2 inhibitor venetoclax (VEN) or placebo (PBO) plus low-dose cytarabine (LDAC) ... https://library.ehaweb.org AML - EHA25 Virtual: 6-Month VIALE-C Update on Venetoclax ...
EHA25 Virtual: 6-Month VIALE-C Update on Venetoclax With Low-Dose Cytarabine in AML. By: Joseph Fanelli Posted: Wednesday, July 8, 2020. http://jnccn360.org |